12:00 AM
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Kyprolis carfilzomib: Phase II data

Researchers at the Dana Farber Cancer Institute and colleagues reported data from an open-label, U.S. Phase II trial in 31 patients with Waldenstrom's macroglobulinemia who were naïve to treatment with a proteasome inhibitor and rituximab showing that IV Kyprolis plus rituximab and dexamethasone led to an ORR of 81%, including 1 complete response, 8 very good partial responses, 12 partial responses and 4 minor responses. Median time to response was 2.1 months. The researchers also said 30 patients concluded induction therapy...

Read the full 385 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >